BeiGene
BGNE
#966
Rank
NZ$35.38 B
Marketcap
$323.43
Share price
0.49%
Change (1 day)
21.39%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$27.43

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$29.14. In 2022 the company made an earnings per share (EPS) of -$33.92 a decrease over its 2021 EPS that were of -$26.63.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$27.43-19.13%
2022-$33.9227.35%
2021-$26.63-19.96%
2020-$33.2720.81%
2019-$27.5431.52%
2018-$20.94417.57%
2017-$4.05-37.16%
2016-$6.44158.95%
2015-$2.49

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.75-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.47-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA